SANUWAVE Health, Inc. (SNWV)
| Market Cap | 196.29M |
| Revenue (ttm) | 29.30M |
| Net Income (ttm) | -389.00K |
| Shares Out | 8.53M |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,992 |
| Open | 22.25 |
| Previous Close | 22.50 |
| Day's Range | 21.00 - 22.25 |
| 52-Week Range | 4.28 - 24.00 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 26, 2025 |
About SANUWAVE Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company’s pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and othe... [Read more]
Financial Performance
In 2023, SANUWAVE Health's revenue was $20.40 million, an increase of 21.84% compared to the previous year's $16.74 million. Losses were -$25.81 million, 150.7% more than in 2022.
Financial StatementsNews
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results
Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results
EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Announces 1-For-375 Reverse Stock Split
Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024 EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), ...
SANUWAVE Health Inc. (SNWV) Q2 2024 Earnings Call Transcript
SANUWAVE Health Inc. (OTCQB:SNWV) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Morgan Frank - Chairman and Chief Executive Officer Peter Sorensen - Chief Financial ...
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results
Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results
EDEN PRAIRIE, MN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host...
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history.
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE
SANUWAVE Health Inc. (SNWV) Q4 2023 Earnings Call Transcript
SANUWAVE Health Inc. (SNWV) Q4 2023 Earnings Call Transcript
SANUWAVE Announces Record Q4 and FY2023 Revenue
Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating l...
SANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial Results
EDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “against” wit...
SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
EDEN PRAIRIE, MN, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023
SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company.
SANUWAVE Announces Q3 2023 Financial Results
EDEN PRAIRIE, MN,, Nov. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial Results
EDEN PRAIRIE, MN, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call ...
SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023
SANUWAVE is Pleased to Announce Preliminary Revenues of $4.7 Million to $4.9 Million for the Third Quarter Ended September 30, 2023 Results Indicate 13-18% Growth Rate Over Q3 2022 UltraMist Revenues ...
SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company
SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). Upon closing, the combined company is expected to trade on the Nasdaq Capit...
SANUWAVE Announces Q2 2023 Financial Results
EDEN PRAIRIE, MN, Aug. 11, 2023 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today ann...
SANUWAVE Will Host a Live Conference Call on August 11, 2023 at 8:30 AM (EDT) to Present Its Q2 2023 Financial Results
EDEN PRAIRIE, MN, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live con...
SANUWAVE Signs Distribution Agreement With Pacific Medical, Inc.
Pacific Medical to bring its sales force of over 215 dedicated representatives covering seven western states to the SANUWAVE UltraMist line of directed energy wound care products.
SANUWAVE Health Appoints Industry Veteran Andrew Walko as President
Walko brings 17 years of Manufacturing, Production, Operations, and Logistics Experience, most recently as President of Biomerics, where he led a 170-person contract manufacturing organization
SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter Ended June 30, 2023
SANUWAVE is pleased to announce preliminary revenues of $4.5 million to $4.7 million for Q2 ended June 30, 2023 Results indicate 16-21% growth rate over Q2 2022, consistent with guidance provided in t...
SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer
Frank Brings 29 Years of Experience in Life Sciences, Technology, and Capital Markets Kevin Richardson to Remain at SANUWAVE as Chief Strategic Officer and as a Member of the Board of Directors EDEN P...
SANUWAVE Announces Q1 2023 Financial Results
EDEN PRAIRIE, MN, May 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st q...